Dengue vaccines: recent developments, ongoing challenges and current candidates

被引:70
作者
McArthur, Monica A. [1 ,3 ]
Sztein, Marcelo B. [1 ,3 ]
Edelman, Robert [2 ,3 ]
机构
[1] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA
[2] Univ Maryland, Dept Med, Sch Med, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA
基金
美国国家卫生研究院;
关键词
antibody-dependent enhancement; dengue fever; dengue hemorrhagic fever; dengue virus; immunopathogenesis; vaccine; ANTIBODY-DEPENDENT ENHANCEMENT; PLATELET-ACTIVATING-FACTOR; ENVELOPE DOMAIN III; T-CELL RESPONSES; PHASE-I TRIAL; HEMORRHAGIC-FEVER; VIRUS-INFECTIONS; CRYSTAL-STRUCTURE; RECOMBINANT SUBUNIT; PROTECTIVE EFFICACY;
D O I
10.1586/14760584.2013.815412
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Dengue is among the most prevalent and important arbovirus diseases of humans. To effectively control this rapidly spreading disease, control of the vector mosquito and a safe and efficacious vaccine are critical. Despite considerable efforts, the development of a successful vaccine has remained elusive. Multiple factors have complicated the creation of a successful vaccine, not the least of which are the complex, immune-mediated responses against four antigenically distinct serotypes necessitating a tetravalent vaccine providing long-lasting protective immunity. Despite the multiple impediments, there are currently many promising vaccine candidates in preclinical and clinical development. Here, the recent advances in dengue virus vaccine development are reviewed and the challenges associated with the use of these vaccines as a public health tool are briefly discussed.
引用
收藏
页码:933 / 953
页数:21
相关论文
共 148 条
[1]   Human immune responses and potential for vaccine assessment in humanized mice [J].
Akkina, Ramesh .
CURRENT OPINION IN IMMUNOLOGY, 2013, 25 (03) :403-409
[2]   Neutralizing antibody response variation against dengue 3 strains [J].
Alvarez, Mayling ;
Pavon-Oro, Alequis ;
Rodriguez-Roche, Rosmari ;
Bernardo, Lidice ;
Morier, Luis ;
Sanchez, Lizet ;
Alvarez, Angel M. ;
Guzman, Maria G. .
JOURNAL OF MEDICAL VIROLOGY, 2008, 80 (10) :1783-1789
[3]   Dengue-specific CD8+ T cells have both protective and pathogenic roles in dengue virus infection [J].
An, J ;
Zhou, DS ;
Zhang, JL ;
Morida, H ;
Wang, JL ;
Yasui, K .
IMMUNOLOGY LETTERS, 2004, 95 (02) :167-174
[4]  
[Anonymous], 2019, Dengue Guidelines for Diagnosis, Treatment, Prevention and Control
[5]  
[Anonymous], GUID CLIN EV DENG VA
[6]  
[Anonymous], 1997, Dengue hemorrhagic fever: Diagnosis, treatment, prevention and control, V2nd
[7]   Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice [J].
Arora, Upasana ;
Tyagi, Poornima ;
Swaminathan, Sathyamangalam ;
Khanna, Navin .
VACCINE, 2013, 31 (06) :873-878
[8]   Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2 [J].
Arora, Upasana ;
Tyagi, Poornima ;
Swaminathan, Sathyamangalam ;
Khanna, Navin .
JOURNAL OF NANOBIOTECHNOLOGY, 2012, 10
[9]  
Atrasheuskaya A, 2003, FEMS IMMUNOL MED MIC, V35, P33, DOI 10.1111/j.1574-695X.2003.tb00646.x
[10]   Vascular leakage in severe dengue virus infections: A potential role for the nonstructural viral protein NS1 and complement [J].
Avirutnan, P ;
Punyadee, N ;
Noisakran, S ;
Komoltri, C ;
Thiemmeca, S ;
Auethavornanan, K ;
Jairungsri, A ;
Kanlaya, R ;
Tangthawornchaikul, N ;
Puttikhunt, C ;
Pattanakitsakul, SN ;
Yenchitsomanus, PT ;
Mongkolsapaya, J ;
Kasinrerk, W ;
Sittisombut, N ;
Husmann, M ;
Blettner, M ;
Vasanawathana, S ;
Bhakdi, S ;
Malasit, P .
JOURNAL OF INFECTIOUS DISEASES, 2006, 193 (08) :1078-1088